Nasal Airway Obstruction Clinical Trial
— NovapakOfficial title:
Novapak Prospective Observational Clinical Trial
NCT number | NCT05747014 |
Other study ID # | MDT 22031 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 9, 2023 |
Est. completion date | December 13, 2023 |
Verified date | March 2024 |
Source | Medtronic Surgical Technologies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The Novapak study is a prospective, observational, multi-site, non-controlled, non-randomized, case-series, with a 2 week and 1-month follow-up in adults undergoing nasal/sinus surgery with Novapak Nasal Sinus Packing and Stent device used as indicated post-operatively and is being conducted to obtain clinical data on the safety and effectiveness of the Novapak device under use as intended in the device indications.
Status | Completed |
Enrollment | 86 |
Est. completion date | December 13, 2023 |
Est. primary completion date | December 13, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is at least 18 years of age. 2. Subject undergoing nasal/sinus surgery with the intended need for nasal sinus packing (i.e., Novapak). 3. After being informed of the nature of the study; the subject understands, agrees to its provisions, is willing to participate and provide written consent. 4. Mentally stable and able to follow the instructions for self-assessment/questionnaire completion. Exclusion Criteria: 1. Subject has a shellfish allergy. 2. Subject has known bleeding disorder or prescribed anticoagulants. 3. Subject has craniofacial abnormalities that may interfere with access to the sinuses. 4. Subject is immunocompromised (e.g., taking immunosuppressive medication). 5. Subject is participating in another investigational device, biologic, or drug study and has not completed the primary endpoint(s) or if there is a potential for clinical interference beyond the primary endpoint. |
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Health Care | London | Onterio |
United States | ENT Associates of South Florida | Boca Raton | Florida |
United States | University of Miami | Miami | Florida |
United States | University of South Florida | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Medtronic Surgical Technologies |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Novapak Safety Assessment | Outcome Measure #1 for the Primary Outcome is the total number of Adverse Events that are directly attributed to the device and/or those that cannot be determined. | 30 days | |
Primary | Novapak Safety Assessment | Outcome Measure #2 for the Primary Outcome is the total number of Adverse Events. | 30 days | |
Secondary | Novapak Effectiveness Assessment | Outcome Measure #3 for the Secondary Outcome Measures is number of adhesions from procedure through 1-month post treatment. | 30 days | |
Secondary | Novapak Effectiveness Assessment | Outcome Measure #4 for the Secondary Outcome Measures is the graded percentage of vertical height of the middle turbinate taken up by the adhesion using an ordinal scale (0-3) from procedure through 1-month post treatment. | 30 days | |
Secondary | Novapak Effectiveness Assessment | Outcome Measure #5 for the Secondary Outcome Measures is to measure control of bleeding by comparing Boezaart Surgical Field Grading Scale scores post operatively, prior to Novapak insertion and post Novapak insertion. | 1 day | |
Secondary | Novapak Effectiveness Assessment | Outcome Measure #6 for the Secondary Outcome Measures is to measure healing by comparing Lund-Kennedy scores before surgery and at 2 weeks and 1-month post treatment. | 30 day | |
Secondary | Novapak Effectiveness Assessment | Outcome Measure #7 for the Secondary Outcome Measures is to measure health by comparing subject scores from the SNOT-22 questionnaire before surgery and at 2 weeks and 1-month post treatment. | 30 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01960816 -
InFlux System for Nasal Breathing Improvement
|
N/A | |
Enrolling by invitation |
NCT03233373 -
Thermal Imaging as a Potential Diagnostic Tool of Nasal Airflow
|
||
Recruiting |
NCT05527652 -
Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia
|
N/A | |
Recruiting |
NCT06163404 -
Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
|
N/A | |
Active, not recruiting |
NCT04549545 -
Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study
|
N/A | |
Active, not recruiting |
NCT05446714 -
Evaluation of the Effect of Three Types of Rapid Maxillary Expanders (Conventional, Hybrid and MSE)
|
N/A |